Baricitinib - CAS 1187594-09-7
Catalog number:
1187594-09-7
Category:
Inhibitor
Not Intended for Therapeutic Use. For research use only.
COA:
Inquire
Targets:
JAK
Description:
Baricitinib, also known as INCB028050 or LY3009104, is a selective orally bioavailable JAK1/JAK2 inhibitor with nanomolar potency against JAK1 (5.9 nM) and JAK2 (5.7 nM). INCB028050 inhibits intracellular signaling of multiple proinflammatory cytokines including IL-6 and IL-23 at concentrations <50 nM. INCB028050 was effective in multiple murine models of arthritis, with no evidence of suppression of humoral immunity or adverse hematologic effects.
Publictions citing BOC Sciences Products
  • >> More
Purity:
0.98
Appearance:
white solid powder
Synonyms:
INCB028050; LY3009104.
MSDS:
Inquire
Current Developer:
Eli Lilly and Company
1.Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate.
Keystone EC1, Taylor PC2, Drescher E3, Schlichting DE4, Beattie SD4, Berclaz PY4, Lee CH4, Fidelus-Gort RK5, Luchi ME5, Rooney TP4, Macias WL4, Genovese MC6. Ann Rheum Dis. 2015 Feb;74(2):333-40. doi: 10.1136/annrheumdis-2014-206478. Epub 2014 Nov 27.
OBJECTIVES: To investigate baricitinib (LY3009104, formerly INCB028050), a novel, oral inhibitor of JAK1/JAK2 in patients with moderate to severe rheumatoid arthritis (RA) despite treatment with methotrexate.
2.Baricitinib in Patients with Refractory Rheumatoid Arthritis.
Genovese MC1, Kremer J1, Zamani O1, Ludivico C1, Krogulec M1, Xie L1, Beattie SD1, Koch AE1, Cardillo TE1, Rooney TP1, Macias WL1, de Bono S1, Schlichting DE1, Smolen JS1. N Engl J Med. 2016 Mar 31;374(13):1243-52. doi: 10.1056/NEJMoa1507247.
BACKGROUND: In phase 2 studies, baricitinib, an oral Janus kinase 1 and 2 inhibitor, reduced disease activity in patients with rheumatoid arthritis who had not previously received treatment with biologic disease-modifying antirheumatic drugs (DMARDs).
3.Reversal of Alopecia Areata Following Treatment With the JAK1/2 Inhibitor Baricitinib.
Jabbari A1, Dai Z1, Xing L2, Cerise JE1, Ramot Y3, Berkun Y4, Sanchez GA5, Goldbach-Mansky R5, Christiano AM6, Clynes R7, Zlotogorski A3. EBioMedicine. 2015 Feb 26;2(4):351-5. doi: 10.1016/j.ebiom.2015.02.015. eCollection 2015.
BACKGROUND: Alopecia areata (AA) is an autoimmune disease resulting in hair loss with devastating psychosocial consequences. Despite its high prevalence, there are no FDA-approved treatments for AA. Prior studies have identified a prominent interferon signature in AA, which signals through JAK molecules.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related JAK Products


CAS 1092578-46-5 (3R,4S)-Tofacitinib

(3R,4S)-Tofacitinib
(CAS: 1092578-46-5)

Tofacitinib is a novel inhibitor of JAK3 with IC50 of 1 nM, 20- to 100-fold less potent against JAK2 and JAK1.

CAS 1056636-06-6 CYT387 sulfate salt

CYT387 sulfate salt
(CAS: 1056636-06-6)

CYT387 sulfate is an ATP-competitive inhibitor of JAK1/JAK2 with IC50 of 11 nM/18 nM, ~10-fold selectivity versus JAK3.

CAS 1640292-55-2 Oclacitinib Maleate

Oclacitinib Maleate
(CAS: 1640292-55-2)

Oclacitinib, also called as PF-03394197, is a novel inhibitor of JAK family members (IC50= 10 - 99 nM) and JAK1-dependent cytokines involved in allergy, inflamm...

CAS 1204918-72-8 SB1317

SB1317
(CAS: 1204918-72-8)

SB1317 is a novel small molecule potent CDK/JAK2/FLT3 inhibitor. It dose-dependently inhibits signaling pathways downstream of CDKs, JAK2 and FLT3 in cancer cel...

CAS 1092939-16-6 Ruxolitinib sulfate

Ruxolitinib sulfate
(CAS: 1092939-16-6)

Ruxolitinib sulfate (INCB018424) is the first potent, selective, JAK1/2 inhibitor to enter the clinic with IC50 of 3.3 nM/2.8 nM, >130-fold selectivity for JAK1...

CAS 1021868-92-7 ZM 39923 HCl

ZM 39923 HCl
(CAS: 1021868-92-7)

Selective inhibitor of Janus tyrosine kinase 3 (JAK3). pIC50 values are 7.1, 5.6, 4.4, and < 5.0 for JAK3, EGFR, JAK1 and CDK4 respectively. Breaks down in neut...

CAS 857064-38-1 WP1066

WP1066
(CAS: 857064-38-1)

WP1066 is a Stat3 inhibitor and JAK2 inhibitor. WP1066 is also a novel analogue of the JAK2 inhibitor AG490, in JAK2 V617F-positive erythroleukemia HEL cells a...

CAS 540737-29-9 Tofacitinib Citrate

Tofacitinib Citrate
(CAS: 540737-29-9)

Tofacitinib (trade name Xeljanz, formerly tasocitinib, CP-690550) is a drug discovered and developed by Pfizer. It is currently approved for the treatment of rh...

CAS 457081-03-7 Pyridone 6

Pyridone 6
(CAS: 457081-03-7)

Pyridone 6 is a potent and selective inhibitor of JAK1, JAK2, JAK3, and Tyk2, displaying significantly weaker affinities for other protein tyrosine kinases. It ...

CAS 477600-75-2 Tofacitinib

Tofacitinib
(CAS: 477600-75-2)

Tofacitinib (CP-690550,Tasocitinib) is a novel inhibitor of JAK3 with IC50 of 1 nM, 20- to 100-fold less potent against JAK2 and JAK1.It is currently approved f...

CAS 80418-25-3 20(S)-Notoginsenoside R2

20(S)-Notoginsenoside R2
(CAS: 80418-25-3)

20(S)-Notoginsenoside R2 is a natural product extracted from the roots of Panax notoginseng (Burk.) F.H.Chen. It has neuroprotection against 6-OHDA-induced neur...

CAS 1187594-09-7 Baricitinib

Baricitinib
(CAS: 1187594-09-7)

Baricitinib, also known as INCB028050 or LY3009104, is a selective orally bioavailable JAK1/JAK2 inhibitor with nanomolar potency against JAK1 (5.9 nM) and JAK...

CAS 1092499-93-8 NVP-BSK805

NVP-BSK805
(CAS: 1092499-93-8)

NVP-BSK805, a quinoxaline derivative, is a selective ATP-competitive JAK2 inhibitor which could induce apoptosis (GI50 < 100 nM) and restrain the growth of JAK2...

CAS 944842-54-0 Decernotinib

Decernotinib
(CAS: 944842-54-0)

Decernotinib, also known as VX-509 or VRT-831509 or adelatinib, is an oral, selective Janus kinase 3 (JAK3) inhibitor being developed by Vertex. VX-509 may repr...

CAS 1229236-86-5 LY2784544

LY2784544
(CAS: 1229236-86-5)

Gandotinib is a potent and selective JAK inhibitor, which effectively inhibited JAK2V617F-driven signaling and cell proliferation in Ba/F3 cells (IC50=20 and 55...

CAS 1092578-48-7 (3S,4R)-Tofacitinib

(3S,4R)-Tofacitinib
(CAS: 1092578-48-7)

Tofacitinib is a novel inhibitor of JAK3 with IC50 of 1 nM, 20- to 100-fold less potent against JAK2 and JAK1.

Itacitinib
(CAS: 1334298-90-6)

Itacitinib is a potent Janus kinase-1 inhibitor under the development of AstraZeneca and Incyte Corporation. Itacitinib can inhibit OCT2-mediated uptake of crea...

CAS 1092578-47-6 (3S,4S)-Tofacitinib

(3S,4S)-Tofacitinib
(CAS: 1092578-47-6)

Tofacitinib is a novel inhibitor of JAK3 with IC50 of 1 nM, 20- to 100-fold less potent against JAK2 and JAK1.

CAS 1208319-27-0 Oclacitinib maleate

Oclacitinib maleate
(CAS: 1208319-27-0)

Oclacitinib maleate was the first selective Janus kinase (JAK) inhibitor to be developed for dogs. Oclacitinib is most potent at inhibiting JAK1 (IC50=10 nM).

BMT-1438

BMT-1438 is a selective inhibitor of Janus kinase (JAK) family with less side effcts which is potentially used for the treatment of rheumatoid arthritis and oth...

Chemical Structure

CAS 1187594-09-7 Baricitinib

Quick Inquiry

Verification code

Featured Items